21 completed, 5 terminated, 5 unknown, 3 active not recruiting. 43 Phase 2, 9 Phase 3, 2 Phase 1.
Follow Anorexia: new trials by email Literature Review of Anorexia trials Research Report on Anorexia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open Trial of a Novel Pharmacotherapy for Habit Modification in Anorexia Nervosa Donepezil - Anorexia Nervosa | Phase 2 | Not yet recruiting | New York State Psychiatric Institute | 10 | 2027-01-01 | 2026-10-23 |
| Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC Rilogrotug, Placebo - Cachexia; Cancer, Cachexia | Phase 2 / Phase 3 | Not yet recruiting | AVEO Pharmaceuticals, Inc. | 950 | 2026-11-01 | 2026-10-28 |
| Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy Nanocrystalline megestrol acetate, Placebo - Hepatocellular Carcinoma (HCC), Cachexia | Phase 2 | Not yet recruiting | Nanfang Hospital, Southern Medical University | 88 | 2026-06-22 | 2026-05-04 |
| Visugromab in Cachexia International Trial Visugromab (CTL-002), Placebo - Cancer-associated Cachexia | Phase 2 / Phase 3 | Recruiting | CatalYm GmbH | 518 | 2026-04-16 | 2026-09-22 |
| A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue ponsegromab, placebo - Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | Pfizer | 982 | 2025-10-03 | 2026-10-14 |
| Ketamine Effects on Learning In Eating Disorders Ketamine infusion - Anorexia Nervosa, Atypical Anorexia Nervosa | Phase 2 | Enrolling by invitation | Amanda Downey, MD | 20 | 2025-06-05 | 2026-10-13 |
| Effect of GLP-1 Analogue ROSE-010 on Appetite in Overweight and Obese Subjects ROSE-010 99 mcg, Placebo, ROSE-010 150 mcg - Obesity; Overweight | Phase 2 | Completed | Rose Pharma Inc | 40 | 2024-09-26 | 2026-06-01 |
| Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer Olanzapine, Placebo Administration, Questionnaire Administration - Advanced Malignant Solid Neoplasm, Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | OHSU Knight Cancer Institute | 66 | 2024-07-17 | 2026-07-16 |
| Anamorelin Study for Advanced Pancreatic Cancer Anamorelin Hydrochloride, Placebo - Metastatic Pancreatic Cancer | Phase 2 | Terminated | Lahey Clinic | 4 | 2023-04-01 | 2025-11-17 |
| Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15 ponsegromab, Placebo for ponsegromab - Non-small Cell Lung Cancer, Pancreatic Cancer | Phase 2 | Completed | Pfizer | 187 | 2022-11-21 | 2026-06-03 |
| Mirtazapine Versus Megestrol Acetate in Treatment of Anorexia-cachexia in Advanced Cancer Patients. Mirtazapine, Megestrol Acetate - Anorexia | Phase 2 | Unknown | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | 80 | 2022-06-01 | 2022-05-18 |
| Determination of In-vivo Plasma AA Appearance From Plant Protein Fibre Products Net peripheral AA appearance following ingestion of 3 selected PPF products compared to whey - Aging, Undernutrition | Phase 2 | Completed | University College Dublin | 9 | 2022-03-14 | 2022-09-26 |
| Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy Psilocybin - Anorexia Nervosa | Phase 2 | Completed | University of California, San Diego | 16 | 2021-05-01 | 2022-07-25 |
| Comparison Between Mirtazapine and Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care. Mirtazapine, Megestrol - Cachexia; Cancer, Anorexia | Phase 2 | Completed | University of Sao Paulo | 52 | 2019-03-26 | 2023-07-07 |
| Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer Anamorelin Hydrochloride, Placebo, Questionnaire Administration - Anorexia, Lung Non-Small Cell Carcinoma | Phase 2 / Phase 3 | Active not recruiting | M.D. Anderson Cancer Center | 25 | 2018-11-27 | 2026-10-06 |
| The Effect of Cannabis in Pancreatic Cancer THC and CBD Mixture - Neoplasms Pancreatic, Cachexia; Cancer | Phase 2 | Withdrawn | Jens Rikardt Andersen | 2017-10-06 | 2023-12-18 | |
| The Safety and Effect Study of Acupuncture for Anorexia in Patients With Gastrointestinal Tract and Lung Cancers Acupuncture, Sham Acupuncture, Megestrol Acetate - Anorexia, Cancer Cachexia | Phase 2 / Phase 3 | Unknown | Xinqiao Hospital of Chongqing | 160 | 2015-12-01 | 2015-12-04 |
| Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Lung Cancer Patients Nabilone, Placebo - Non-Small Cell Lung Cancer, Anorexia | Phase 2 / Phase 3 | Unknown | Instituto Nacional de Cancerologia de Mexico | 78 | 2014-12-01 | 2016-08-31 |
| Megestrol Acetate With or Without Mirtazapine in Treating Cancer Patients With Weight Loss or Loss of Appetite Megestrol Acetate, Mirtazapine - Anorexia | Phase 2 | Withdrawn | Washington University School of Medicine | 2013-09-01 | 2014-02-03 | |
| Phase 2 Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa RM-131, Placebo - Anorexia Nervosa | Phase 2 | Completed | Motus Therapeutics, Inc. | 20 | 2012-11-01 | 2016-09-23 |
Showing 20 of 43. Sign in to see all of them.
Cachexia (19) · Weight Loss (15) · Neoplasms (9) · Anorexia Nervosa (6) · Fatigue (6) · Carcinoma, Non-Small-Cell Lung (5) · Feeding and Eating Disorders (5) · Pancreatic Neoplasms (5) · Colorectal Neoplasms (3) · Malnutrition (3) · Obesity (3) · Overweight (3) · Body Weight Changes (2) · Depression (2)
Pathological Conditions, Signs and Symptoms (43) · Signs and Symptoms (43) · Signs and Symptoms, Digestive (43) · Body Weight (27) · Body Weight Changes (24) · Thinness (19) · Neoplasms by Site (12) · Weight Loss (10) · Digestive System Diseases (8) · Digestive System Neoplasms (8) · Mental Disorders (8) · Neoplasms (7) · Nutrition Disorders (7) · Nutritional and Metabolic Diseases (7) · Bronchial Neoplasms (5)
Megestrol Acetate (7) · Mirtazapine (4) · Olanzapine (2) · anamorelin (2) · lorcaserin (2) · Acupuncture Therapy (1) · Calcium Dobesilate (1) · Dexamethasone (1) · Donepezil (1) · Dronabinol (1) · EOM613 (1) · Family Therapy (1) · Fish Oils (1) · Flurandrenolone (1) · Gemcitabine (1)
M.D. Anderson Cancer Center (6) · Eisai Inc. (2) · Pfizer (2) · AVEO Pharmaceuticals, Inc. (1) · Alberta Health services (1) · Amanda Downey, MD (1) · Anaborex (1) · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh (1) · Bristol-Myers Squibb (1) · CatalYm GmbH (1) · Centocor, Inc. (1) · Changhua Christian Hospital (1) · Charite University, Berlin, Germany (1) · Endo USA Inc., a Keenova Therapeutics Company (1) · Faculdade de Medicina do ABC (1)
United States (26) · China (6) · Canada (4) · Taiwan (4) · Brazil (3) · Bulgaria (3) · Germany (3) · India (3) · Italy (3) · Poland (3) · Spain (3) · Australia (2) · France (2) · Japan (2) · Mexico (2)
Agop Y. Bedikian, MD (1) · Alexander Ginting (1) · Amanda E. Downey, MD (1) · Anne Klibanski, MD (1) · Benjamin LI, Ph.D. (1) · Biswa Mohan Biswal (1) · Chang-yao Tsao (1) · Chaoting Zhao, MD (1) · Cheng-ta Yang (1) · Chung-kong Kwan (1) · Claudia Latorre (1)
PMID 21343383, PMID 36999619, PMID 11786587, PMID 12457271, PMID 12648025, PMID 15778874, PMID 15857739, PMID 16317825, PMID 16376734, PMID 16408219, PMID 1666930, PMID 16849753, PMID 17566383, PMID 17589370, PMID 18257397, PMID 18402303, PMID 18728826, PMID 19057523, PMID 19587829, PMID 19883531, PMID 19896326, PMID 20076976, PMID 22076835, PMID 23141881, PMID 25524795, PMID 26883879, PMID 27403414, PMID 29325236, PMID 29550881, PMID 37488291, PMID 3774823, PMID 38197040, PMID 38500292, PMID 38988455, PMID 39282907, PMID 8035251, PMID 8558188
2023 (1), 2025 (1), KL2TR001870 (1), P30CA069533 (1), R01MH070620 (1)